LinqMed Inc.
PrivateLast Round
Series B
Extension
May 12, 2025
Total Funding Raised
$39.55M
Company Overview
LinqMed Inc. operates in Healthcare & Life Sciences and is based in Chiba, Tokyo. Its latest recorded funding round was a Series B Extension round in May 2025.
LinqMed Inc. is a radiopharmaceutical company developing a drug discovery platform and innovative 'visible' anti-cancer treatments using the copper radioisotope 64Cu.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Medical Imaging, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts, Data as a Service
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
LinqMed Inc. Comparables
Compare LinqMed Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Alpha Fusion Inc. | 81% | |
| NUCLIDIUM AG | 80% | |
| RadioMedix, Inc. | 77% |
For institutional investors. Book with your work email.
LinqMed Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | May 12, 2025 | ||||
| Series B Extension | Apr 9, 2025 | ||||
| Series B | Jan 10, 2025 | ||||
| Series A | Dec 22, 2023 | ||||
| Grant | Dec 22, 2023 |
For institutional investors. Book with your work email.
LinqMed Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Sumitomo Mitsui Trust Bank | Series B Extension |
| Keio Innovation Initiative | Series B Extension |
| Mizuho Capital | Series A |
| New Energy and Industrial Technology Development Organization | Grant |
| Chibagin Capital | Series B Extension |
| Bio-Sight Capital | Series A, Series B Extension |
| Nissay Capital | Series B Extension |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- May 12, 2025
$2M round with Nissay Capital participating.
- Apr 9, 2025
$14.47M round with Sumitomo Mitsui Trust Bank and Chibagin Capital.
For institutional investors. Book with your work email.
LinqMed Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about LinqMed Inc.'s valuation, stock price, and market status.
Is LinqMed Inc. a public or private company?
LinqMed Inc. is a private company.
What is the current stock price of LinqMed Inc.?
LinqMed Inc. is a private company, so its shares have no public market price. Caplight tracks LinqMed Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is LinqMed Inc. worth (valuation)?
Valuation information for LinqMed Inc. is not publicly available.
Can I buy LinqMed Inc. stock?
LinqMed Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was LinqMed Inc.'s last funding round?
LinqMed Inc.'s most recent funding round was Series B Extension on May 12, 2025.
Who are the main investors in LinqMed Inc.?
Key investors in LinqMed Inc. include JIC Venture Growth Investments, DBJ Capital.
Will LinqMed Inc. IPO soon?
No public IPO plans have been announced for LinqMed Inc..
How can I track LinqMed Inc. secondary market activity?
Caplight tracks bids, offers, and trades in LinqMed Inc.'s shares on secondary markets.